Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AB-201 |
Synonyms | |
Therapy Description |
AB-201 are cord-blood derived natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) that targets ERBB2 (HER2), which potentially results in tumor cell killing and growth inhibition in ERBB2 (HER2)-expressing tumors (Journal for ImmunoTherapy of Cancer 2021;9). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AB-201 | AB 201|AB201 | AB-201 are cord-blood derived natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) that targets ERBB2 (HER2), which potentially results in tumor cell killing and growth inhibition in ERBB2 (HER2)-expressing tumors (Journal for ImmunoTherapy of Cancer 2021;9). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05678205 | Phase Ib/II | AB-201 Cyclophosphamide + Fludarabine | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | Not yet recruiting | USA | 1 |
NCT06341647 | Phase I | Cyclophosphamide + Fludarabine AB-201 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | Not yet recruiting | AUS | 0 |